Open questions — remedy-regulation (round 13)

• Do commercially sold borage seed oil capsules (UK/SA) actually contain measurable unsaturated pyrrolizidine alkaloids, and is any product certified PA-free for children?
• How often does topical almond (or other nut) oil cause clinically relevant tree-nut sensitisation in toddlers with AD — is there any cohort data beyond the Guillet 2000 case report?
• Does Eczema Care Online improve outcomes specifically in the 1–4 age subgroup, and does it change topical steroid use or adherence (not reported in the abstract)?
• How often do UK/EU products labelled “fragrance-free” still contain named Annex III fragrance allergens after the 2023/1545 transition?